Page 81 - பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் Today - Breaking & Trending Today

President's Speaker Series Welcomes Moderna CEO and Leading Experts to Discuss COVID-19 Vaccine


Recognizing the current global and national focus on the development and distribution of COVID-19 vaccines, the March 2021 installment of the President’s Speaker Series will present a moderated panel of leading medical, pharmaceutical, and biotechnology experts who will share their professional knowledge and experience with COVID-19 vaccines and examine what society might expect from vaccines in the future.
Stéphane Bancel, chief executive officer of Moderna, Stephen M. Hahn, former commissioner of food and drugs at the US Food and Drug Administration, and Jonathan B. Perlin, president of the Clinical Services Group and chief medical officer of HCA Healthcare, will present “Vaccines: Where Are We and Where Are We Going?” via Zoom on Monday, March 29, at 5 PM PDT. Dee Anna Smith (’86), CEO of Sarah Cannon, the Cancer Institute of HCA Healthcare, and chair of the Pepperdine Board of Regents, will moderate the discussion. ....

United States , France General , United Kingdom , San Francisco , Museum Of Science , Meharry Medical College , Rice University , Jonathanb Perlin , Dee Anna Smith , Stephenm Hahn , Eli Lilly , Johnm Eisenberg , Research Services , American Institute Of Certified Public Accountants , Us Public Health Service Commissioned Corps , Nashville Entrepreneur Center , Clinical Services Group , National Institute Of Health Cancer , Human Services Health It Standards Committee , University Of Texas Md Anderson Cancer Center , Drug Administration , University Of California , American Society Of Clinical Oncology , Pepperdine University Board Of Regents , Us Department Of Veterans Affairs , Nashville Health Care Council ,

BioSpace Global Roundup, March 11


Published: Mar 11, 2021
By Alex Keown
Saniona, a rare disease-focused company based in Sweden, received feedback from the U.S. Food and Drug Administration (FDA) on a path forward for its hypothalamic obesity (HO) drug Tesomet. Based on guidance from the regulatory agency, Saniona is planning a Phase IIb study in this indication in the first half of this year.
“There is currently no medicine approved for hypothalamic obesity, a rare disease secondary to hypothalamic injury, characterized by intractable weight gain and complicated by uncontrollable hunger,” Rudolf Baumgartner, Chief Medical Officer and Head of Clinical Development at Saniona said in a statement. “We are encouraged by this feedback from the FDA and look forward to continuing a constructive dialogue with them as we prepare to initiate our Phase IIb clinical trial with Tesomet.” ....

United Kingdom , United States , Nordrhein Westfalen , South Korea , Rudolf Baumgartner , Orionis Biosciences , Eli Lilly , Department Of Pure , Contract Development , University Of Strathclyde , Manufacturing Organization , Avacta Group , Israel Biologic Design Ltd , Exelixis Inc , Mainstay Medical Holdings , Therapeutics Limited , Werfen Company , University Of Texas Md Anderson Cancer Center , Drug Administration , Head Of Clinical Development At Saniona , Gigagen Inc , U Avacta Group , Chief Medical Officer , Clinical Development , Risk Evaluation , Mitigation Strategy ,

Press Release : Affimed Announces Presentations at the AACR Annual Meeting 2021


Message :
Required fields
AFM24 preclinical in vivo data will be presented as a poster
Data on AFM13 in combination with adoptive NK cells will be presented
during a Major Symposium
Heidelberg, Germany, March 10, 2021 Affimed N.V. (Nasdaq: AFMD), a
clinical-stage immuno-oncology company committed to giving patients back
their innate ability to fight cancer, announced today that preclinical
anti-tumor efficacy in vivo data from its innate cell engager (ICE(R) )
AFM24 have been accepted for e-poster presentation at the American
Association for Cancer Research (AACR) Virtual Annual Meeting I, being
held on April 10-15.
In addition, early data from a Phase 1 study evaluating AFM13 preloaded ....

United States , New York , Baden Wuberg , Cassandra Choe Juliak , Affimednv Affimed , Gabriele Hintzen , Jens Pahl , Sheena Pinto , Torsten Haneke , Uwe Reusch , Andreas Harstrick , Katy Rezvani , Joachim Koch , Arndt Schottelius , Mary Beth Sandin , Christian Breunig , Wolfgang Fischer , Panel Session , American Association For Cancer Research , University Of Texas Md Anderson Cancer Center , Md Anderson Cancer Center , Department Of Stem Cell Transplantation , Cancer Research Professor Of Medicine , Translational Research , Major Symposium , Cancer Research ,

Palliative Care for Patients With Dementia: When to Refer?